Role of Vitamin D in Reducing the Frequency of Asthma Attacks in Patients with Frequent Exacerbation of Asthma

Mubeen Ahmed Memon a, Sheeba Faryal Ansari b, Mumtaz Ali Lakho b, Mukhtiar Hussain Jaffery b, Syed Zulfiquar Ali Shah b* and Samar Raza b

a Department of Pulmonology, Liaquat University of Medical and Health Sciences (LUMHS), Jamshoro, Pakistan.
b Department of Medicine, Liaquat University of Medical and Health Sciences (LUMHS), Jamshoro, Pakistan.

Authors’ contributions

This work was carried out in collaboration among all authors. Author MAM managed the literature searches and drafting. Author SFA designed the study. Author MAL did the statistical analysis. Author MHJ wrote the protocol and data collection. Author MAM wrote the first draft of the manuscript. Authors SZAS, SR and SFA managed the analyses of the study and data collection. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i53B33675

(1) Dr. Barkat Ali Khan, Gomal University, Pakistan.
(2) Geetanjali Rathore, University of Nebraska Medical Center, USA.
(2) Shweta Mangal, Mahatma Gandhi University of Medical Science Technology, India.

Complete Peer review History, details of the editor(s), Reviewers and additional Reviewers are available here:
https://www.sdiarticle5.com/review-history/77273

ABSTRACT

Introduction: Vitamin D deficiency is common among asthmatics with literature suggesting that its low levels in the body may trigger exacerbations and decrease the response to corticosteroid treatment. It has also shown to inhibit the production of cytokines, which in turn enhances the body’s response to corticosteroid treatment during an exacerbation. Therefore, maintenance of adequate levels of vitamin D in patients with asthma may reduce the risk of exacerbation and improve their general health. This study aims to explore the role of vitamin D supplementation in preventing asthma exacerbations.

Methods: This single blind parallel arm interventional study was conducted in the pulmonology ward in a tertiary care hospital from June 2018 to April 2020. Two hundred (n= 200) participants
Keywords: Vitamin D; asthma; obstructive lung disease; bronchial asthma and acute exacerbation of asthma.

1. INTRODUCTION

Asthma is a chronic obstructive disease of the respiratory tract [1]. The global burden of asthma has increased over the last two decades whereby it now affects approximately 300 million people worldwide, with a predilection towards industrialized countries. The onset of the disease is mostly early in life, with almost 90% of cases diagnosed before the age of six years [1,2].

Asthma is characterized by the presence of hyper-responsive airways with reversible airway obstruction and inflammation, leading to symptoms of cough, wheeze, breathlessness, and chest tightness [3,4]. The acute onset of these symptoms is commonly referred to as an exacerbation. Although there is no proper definition for an asthmatic exacerbation, the literature suggests that onset of worsening symptoms requiring hospital admission, treatment with systemic steroids, or a more than 25% reduction in peak expiratory flow (PEF) indicates an exacerbation [1,5]. These exacerbations are a major cause of morbidity and mortality in this group [6]. Several factors can trigger an attack but exposure to allergens and infections of the respiratory tract are seen to be the main culprits [7]. The exacerbations require urgent inpatient management and can lead to death with a mortality rate of approximately 4000 deaths/year [3].

Vitamin D plays an important immunoregulatory and anti-inflammatory role in the body, and is often linked to asthma [4]. It is seen that vitamin D deficiency is common among asthmatics with literature suggesting that its low levels in the body may trigger exacerbations and decrease the response to corticosteroid treatment. Vitamin D has shown to inhibit the production of cytokines, which in turn enhances the body’s response to corticosteroid treatment during an exacerbation [8,9]. Its unique antimicrobial properties lower the risk of infections, hence reducing the triggers for the exacerbation [10]. Therefore, maintenance of adequate levels of vitamin D in patients with asthma may reduce the risk of exacerbation and improve their general health. This study aims to explore the role of vitamin D supplementation in preventing asthma exacerbations.

2. MATERIALS AND METHODS

This single blind parallel arm interventional study was conducted in the pulmonology ward in a tertiary care hospital from June 2018 to April 2020. Two hundred (n= 200) participants with a history of frequent acute exacerbation of asthma were enrolled in the study via consecutive inclusion of participants’ age, gender, number of asthma exacerbations. It may also help to improve the condition in severe asthmatics with low vitamin D levels.

Results: Compared to day 0, mean episodes of exacerbation in the interventional group were significantly lower after 180 days (1.1 ± 0.4 vs. 0.61 ± 0.3; p-value <0.0001). Similarly, number of asthma attacks in past 7 days was significantly lower in intervention group after 180 days (4.4 ± 2.7 vs. 3.1 ± 1.5; p-value 0.0001)

Conclusion: Vitamin D supplementation is a safe and cost-friendly approach to reducing asthma exacerbations. It may also help to improve the condition in severe asthmatics with low vitamin D levels.

Keywords: Vitamin D; asthma; obstructive lung disease; bronchial asthma and acute exacerbation of asthma.

1. INTRODUCTION

Asthma is a chronic obstructive disease of the respiratory tract [1]. The global burden of asthma has increased over the last two decades whereby it now affects approximately 300 million people worldwide, with a predilection towards industrialized countries. The onset of the disease is mostly early in life, with almost 90% of cases diagnosed before the age of six years [1,2].

Asthma is characterized by the presence of hyper-responsive airways with reversible airway obstruction and inflammation, leading to symptoms of cough, wheeze, breathlessness, and chest tightness [3,4]. The acute onset of these symptoms is commonly referred to as an exacerbation. Although there is no proper definition for an asthmatic exacerbation, the literature suggests that onset of worsening symptoms requiring hospital admission, treatment with systemic steroids, or a more than 25% reduction in peak expiratory flow (PEF) indicates an exacerbation [1,5]. These exacerbations are a major cause of morbidity and mortality in this group [6]. Several factors can trigger an attack but exposure to allergens and infections of the respiratory tract are seen to be the main culprits [7]. The exacerbations require urgent inpatient management and can lead to death with a mortality rate of approximately 4000 deaths/year [3].

Vitamin D plays an important immunoregulatory and anti-inflammatory role in the body, and is often linked to asthma [4]. It is seen that vitamin D deficiency is common among asthmatics with literature suggesting that its low levels in the body may trigger exacerbations and decrease the response to corticosteroid treatment. Vitamin D has shown to inhibit the production of cytokines, which in turn enhances the body's
number of episodes of acute exacerbation in the last six months were noted at time of enrollment and on day 180. Patients were asked to come for follow up at day 90 and day 180. On day 0 after registration, patients in the interventional group were given a vitamin D capsule and patients in placebo were given placebo and were asked to take the medicine in front of the physician. Similar process was reported on day 90. This was done to ensure compliance to the intervention assigned. 15 participants in the interventional group and 17 participants in the placebo group were lost to follow up. Participants who completed the study were included in final analysis.

Statistical analysis was done using Statistical Package for Social Sciences® software version 23.0 (SPSS; IBM Corp., Armonk, NY, USA). Continuous variables were presented as mean and standard deviation. Categorical variables as percentages and frequencies. Dependent t-test was applied to compare the mean values of the interventional and placebo group on day 0 and day 180. A p-value of less than 0.05 represented a difference between the interventional and placebo group and the null hypothesis was void.

3. RESULTS

In this study, the mean age of participants in the interventional group was 34 ± 14 and in placebo, it was 39 ± 16 years. Treatment regime was comparable between both the groups (Table 1).

Compared to day 0, mean episodes of exacerbation in the interventional group were significantly lower after 180 days (1.1 ± 0.4 vs. 0.61 ± 0.3; p-value <0.0001). Similarly, the number of asthma attacks in the past 7 days was significantly lower in the intervention group after 180 days (4.4 ± 2.7 vs. 3.1 ± 1.5; p-value 0.0001) (Table 2).

In Kaplan-Meier survival analysis, the survival probability of not having an event (acute exacerbation) was significantly higher in the intervention cohort than in the placebo cohort (log-rank test, p-value= 0.029) (Fig. 1).

4. DISCUSSION

Our study demonstrated that the group that received vitamin D supplementation showed a significant decrease in the frequency of acute exacerbation. This group also experienced less number of asthma attacks, and the problem of onset of troublesome cough at night was also solved. These results were further analyzed to point towards the fact that vitamin D supplementation could potentially result in favor of not having an asthma exacerbation.

| Variables                              | Interventional group (n=85) | Placebo group (n=83) | p-value |
|----------------------------------------|-----------------------------|----------------------|---------|
| Mean + SD (in years)                   | 34 ± 14                     | 39 ± 16              | NS      |
| Male                                   | 45 (52.9%)                  | 46 (55.4%)           | NS      |
| Smoking                                | 16 (18.8%)                  | 11 (13.3%)           | NS      |
| Exercise                               | 11 (12.9%)                  | 12 (14.5%)           | NS      |
| NSAIDs more than 30 days in last 180 days | 01 (1.2%)              | 02 (2.4%)            | NS      |
| Beta blockers                          | 03 (3.5%)                   | 02 (2.4%)            | NS      |
| Family history of asthma               | 05 (5.9%)                   | 05 (6.0%)            | NS      |
| **Treatment**                          |                             |                      |         |
| Short acting beta agonists             | 72 (84.7%)                  | 74 (89.2%)           | NS      |
| Long acting beta agonists              | 35 (41.2%)                  | 36 (43.4%)           | NS      |
| Montelukast                            | 51 (60.0%)                  | 55 (66.3%)           | NS      |
| Inhaled corticosteroids                | 36 (42.4%)                  | 38 (45.8%)           | NS      |
| Oral corticosteroids                   | 06 (7.1%)                   | 7 (8.4%)             | NS      |
Fig. 1. Kaplan-Meier survival analysis showing comparison between both groups in terms of not having acute exacerbation

Table 2. Comparison of asthma attacks in both groups on day 0 and day 180

| Variables                                      | Interventional Group (n=85) | Placebo Group (n=83) |
|------------------------------------------------|----------------------------|----------------------|
| **Episodes of acute exacerbation in last 180 days** | Day 0: 1.1 ± 0.4           | Day 180: 1.2 ± 0.4    |
|                                                 | p-value < 0.0001           | p-value 0.107        |
| **Number of asthma attacks in the past 7 days**   | Day 0: 4.4 ± 2.7           | Day 180: 4.5 ± 2.6    |
|                                                 | p-value 0.001              | p-value 0.63         |
| **Number of nights with troublesome cough in past 28 days** | Day 0: 10.1 ± 6.2          | Day 180: 12.2 ± 8.1   |
|                                                 | p-value 0.0017             | p-value 0.37         |

There is sufficient evidence supporting the results of our study, stating that vitamin D supplementation is a safe and useful approach in the treatment of asthma [11]. However, Hall et al. reviewed studies and concluded that the intake of vitamin D to cure asthma is controversial [12]. A study suggested that administration of vitamin D for 4 months would potentially lead to better lung functioning, not taking the level of vitamin D into account [13]; on the other hand, other studies did not prove a positive result [14,15]. Moreover, Musharraf et al. reported that asthma exacerbation could be avoided by the help of vitamin D supplementation [16]; whereas some other studies reported quite the opposite [17,18].

The results found in our study can be backed by proof provided by a number of studies that vitamin D affects the cells of innate and adaptive immune systems in addition to the cells of the respiratory tract. Its deficiency triggers inflammation, and its increase via supplements aid in relieving these effects [19,20]. This idea has been supported by many studies that are of the idea that vitamin D supplementation is capable of reducing asthma exacerbations, and helps to improve the condition in severe asthmatics with low vitamin D levels [21-23]. This could also be explained by a fact that people who have low levels of a micronutrient will most likely respond to its substitution.

To the best of our knowledge, this is first study from local setting that studies the role of vitamin D in reducing asthma exacerbation. However, there were some limitations as well. First since, the study was conducted in single center, sample size was less diverse. Secondly, most of lack of resources, patients were followed up for only six months. Further large scale multicenter studies are needed to assess role of vitamin D in asthma.

5. CONCLUSION

In conclusion, our study has proved that vitamin D supplementation is a safe and cost-friendly approach to reducing asthma exacerbations. However, further large scale studies and clinical trials are required to further provide a guideline to the doctors in order to make the best possible use of this supplementation.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors and collaboration of whole research team.
ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

CONSENT

As per international standard or university standard, patients' written consent has been collected and preserved by the author(s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A: Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1392-7. DOI: 10.1164/ajrccm.164.8.2104102

2. Masoli M, Fabian D, Holt S, Beasley R: Global initiative for asthma (GINA) program. The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469-78. DOI: 10.1111/j.1398-9995.2004.00526.x

3. Brehm JM, Celedón JC, Soto-Quirós ME, et al.: Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica. Am J Respir Crit Care Med. 2009;179:765-71. DOI: 10.1164/rccm.200808-1361OC

4. Sandhu MS, Casale TB: The role of vitamin D in asthma. Ann Allergy Asthma Immunol: 2010. DOI: 10.1016/j.anai.2010.01.013

5. Reddel HK, Taylor DR, Bateman ED, et al.: American thoracic society/European respiratory society task force on asthma control and exacerbations. An official American thoracic society/European respiratory society statement: asthma control and exacerbations: Standardizing endpoints for clinical asthma and clinical practice. Am J Respir Crit Care Med. 2009;180:59-99. DOI: 10.1164/rccm.200801-060ST

6. Johnston NW, Sears MR: Asthma exacerbations. 1: Epidemiology. Thorax. 2006;61:722-8. DOI: 10.1136/thx.2005.045161

7. Singh AM, Busse WW: Asthma exacerbations. 2: Aetiology. Thorax. 2006;61:809-16. DOI: 10.1136/thx.2005.045179

8. Nanzer AM, Chambers ES, Ryanna K, et al.: The effects of calcitriol treatment in glucocorticoid-resistant asthma. J Allergy Clin Immunol. 2014;133:1755-7.e4. DOI: 10.1016/j.jaci.2014.03.015

9. Xystrakis E, Kusumakar S, Boswell S, et al.: Reversing the defective induction of IL-10- secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest. 2006;116:146-55. DOI: 10.1172/JCI21759

10. Mann EH, Chambers ES, Pfeffer PE, Hawrylowicz CM.: Immunoregulatory mechanisms of vitamin D relevant to respiratory health and asthma. Ann N Y Acad Sci. 2014;1317:57-69. DOI: 10.1111/nyas.12410

11. Pfeffer PE, Hawrylowicz CM: Vitamin D in asthma: Mechanisms of action and considerations for clinical trials. Chest. 2018;153:1229–39. DOI: 10.1016/j.chest.2017.09.005

12. Hall SC, Agrawal DK: Vitamin D and bronchial asthma: An Overview of Data From the Past 5 Years. Clin Ther. 2017;39:917–29. DOI: 10.1016/j.clinthera.2017.04.002

13. Ali AM, Selim S, Abbassi MM, Sabry NA: Effect of alfalcacidol on the pulmonary function of adult asthmatic patients: A randomized trial. Ann Allergy Asthma Immunol. 2017;118:557–63 DOI: https://doi.org/10.1016/j.anai.2017.02.014

14. Kerley CP, Hutchinson K, Cormican L, Faul J, Greally P, Coghlan D, Elnazar B: Vitamin D3 for uncontrolled childhood asthma: A pilot study. Pediatr. Allergy Immunol. 2016;27:404–12. DOI: 10.1111/pai.12547

15. Rajanandh MG, Nageswari AD, Prathiksha G: Effectiveness of vitamin D3 in severe persistent asthmatic patients: A double blind, randomized, clinical study. J Pharmacol Pharmacother. 2015;6:142-6 DOI: 10.4103/0976-500X.162022

16. Musharraf MU, Sandhu GA, Mumtaz MU, Rashid MF: Role of vitamin D in prevention of acute exacerbation of bronchial asthma
in adults. Journal of Postgraduate Medical Institute. 2017; 31:310–3
Available: https://jpmi.org.pk/index.php/jpmi/article/view/2111

17. Jensen ME, Mailhot G, Alos N, Rousseau E, White JH, Khamessan A, Ducharme FM. Vitamin D intervention in preschoolers with viral-induced asthma (DIVA): A pilot randomised controlled trial. Trials. 2016;17:353.
DOI: 10.1186/s13063-016-1483-1

18. Andújar-Espinosa R, Salinero-González L, Illán-Gómez F, Castilla-Martínez M, Hu-Yang C, Ruiz-López FJ. Effect of vitamin D supplementation on asthma control in patients with vitamin D deficiency: the ACVID randomised clinical trial. Thorax. 2020, thoraxjnl-2019-213936.
DOI: 10.1136/thoraxjnl-2019-213936

19. Mann EH, Chambers ES, Pfeffer PE, Hawrylowicz CM. Immunoregulatory mechanisms of vitamin D relevant to respiratory health and asthma. Ann N Y Acad Sci. 2014;1317:57–69.
DOI: 10.1111/nyas.12410

20. Korn S, Hübner M, Jung M, Blettner M, Buhl R. Severe and uncontrolled adult asthma is associated with vitamin D insufficiency and deficiency. Respir. Res. 2013;14:25.
DOI: https://doi.org/10.1186/1465-9921-14-25

21. Babar MZM, Hussain M, Majeed SA. Vitamin D supplementation improves FEV1 in patients of bronchial asthma. Pak J Med Sci. 2017;33:1144–7.
DOI: 10.12669/pjms.335.12990.

22. Kang Q, Zhang X, Liu S, Huang F. Correlation between the vitamin D levels and asthma attacks in children: Evaluation of the effects of combination therapy of atomization inhalation of budesonide, albuterol and vitamin D supplementation on asthmatic patients. Exp Ther Med. 2018;15:727–32.
DOI: 10.3892/etm.2017.5436.

23. Pfeffer PE. Targeting the exposome: does correcting vitamin D deficiency have potential to treat and prevent asthma. Expert Rev Clin Immunol. 2018;14:241–3.
DOI: 10.1080/1744666X.2018.1440207.

© 2021 Memon et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/77273